Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
This change is part of standard benefits for our fully insured group and individual Commercial members IBX will continue to provide coverage for GLP-1 drugs prescribed to your patients (our members) for FDA-approved medical conditions and indications, including type 2 diabetes and cardiovascular disease, with prior authorization. IBX and several other insurers have made similar decisions in recent months secondary to cost
Delayed gastric emptying, i.e
Popular GLP-1 Medications The GLP-1 landscape includes several widely prescribed options: Semaglutide (Ozempic, Wegovy): For type 2 diabetes and weight management Tirzepatide (Mounjaro): A dual GIP/GLP-1 receptor agonist with significant weight loss effects Liraglutide (Saxenda): Approved specifically for weight management Dulaglutide (Trulicity): Primarily used for type 2 diabetes management Each medication has a unique dosing schedule and side effect profile that your healthcare provider can discuss during personalized consultations
A study of 338 participants, people taking retatrutide showed: 17.5% average weight loss after 24 weeks Up to 24.2% weight loss after 48 weeks 93% lost at least 10% of their body weight Around a quarter lost more than 30% These results are higher than what we typically see with current treatments, though its worth noting this was a smaller study and were waiting for larger phase 3 trials to confirm these findings
More green space is linked to less stress in deprived communities: Evidence from salivary cortisol patterns
US$ 29.41
US$ 26.66
US$ 25.37
US$ 20.78
